Geneva, Switzerland and Boston, MA – November 29, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel…
Month: November 2018
ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
Geneva, Switzerland and Boston, MA – November 28, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
Credit Suisse Healthcare Conference
Click here for webcast Date & Time: 15 Nov 2018 10:00 a.m. ET Location: Scottsdale, AZ
Jefferies London Healthcare Conference
Click here for webcast Date & Time: 14 Nov 2018 10:00 a.m. GMT Location: London
Q3 Report 2018
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from…
ObsEva SA to Participate in November Investor Conferences
Geneva, Switzerland and Boston, MA – November 7, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…